KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.

Circulation · 2025-Jun-10 · PMID 40156843

Panel B质量警告待 EXE 对齐验证

Time to cardiovascular death

Figure 1. Cumulative incidence plots of outcomes for oral semaglutide vs placebo in subgroups with or without SGLT2i use at baseline. A , Time to first occurrence of MACE. B , Time to cardiovascular death. C , Time to first nonfatal myocardial infarction event. D , Time to first nonfatal stroke event. E , Time to all-cause death. The cumulative incidence rate is calculated using the Aalen-Johansen method with noncardiovascular death ( A and B )/all-cause death ( C and D ) as a competing risk. CV indicates cardiovascular; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; and SGLT2i, sodium-glucose cotransporter-2 inhibitor

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.83
质量通过否
预期曲线4
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证22026-07-23T18:08:34+00:00